Drug Profile
GZ 402674
Alternative Names: GZ402674Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sanofi
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Europe
- 26 Jul 2012 Phase-I clinical trials in Solid tumours in Europe (unspecified route)